Geode Capital Management, LLC Sigilon Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.34 - $1.38 $8,942 - $36,294	-26,300 Reduced 21.42%	96,499 $89,000
Q4 2022 Feb 13, 2023	BUY	$0.29 - $0.69 $121 - $289	420 Added 0.34%	122,799 $42,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $0.86 $544 - $975	1,134 Added 0.94%	122,379 $61,000
Q2 2022 Aug 12, 2022	SELL	$0.74 - $1.64 $93,189 - $206,528	-125,932 Reduced 50.95%	121,245 $100,000
Q1 2022 May 13, 2022	BUY	$1.24 - $3.03 $16,149 - $39,462	13,024 Added 5.56%	247,177 $363,000
Q4 2021 Feb 11, 2022	BUY	$2.58 - $6.13 $6,426 - $15,269	2,491 Added 1.08%	234,153 $646,000
Q3 2021 Nov 12, 2021	BUY	$4.42 - $10.61 $432,660 - $1.04 Million	97,887 Added 73.17%	231,662 $1.31 Million
Q2 2021 Aug 13, 2021	BUY	$9.15 - $20.17 $108,290 - $238,711	11,835 Added 9.71%	133,775 $1.44 Million
Q1 2021 May 12, 2021	BUY	$18.76 - $40.91 $1.97 Million - $4.3 Million	105,011 Added 620.3%	121,940 $2.73 Million
Q4 2020 Feb 12, 2021	BUY	$27.6 - $48.03 $467,240 - $813,099	16,929 New	16,929 $813,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.